⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8926152 | 0.95 | ESR2 (0.32) | — | |
| SCHEMBL1941915 | 0.93 | — | — | |
| SCHEMBL1941986 | 0.87 | — | — | |
| SCHEMBL1943309 | 0.85 | — | — | |
| SCHEMBL8616238 | 0.81 | — | — | |
| SCHEMBL4614450 | 0.79 | — | — | |
| SCHEMBL17090752 | 0.79 | — | — | |
| SCHEMBL10880063 | 0.78 | — | — | |
| SCHEMBL21085070 | 0.78 | CYP1A2 (0.31) | — | |
| SCHEMBL3409261 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227601-A1 | Bradykinin 1 Receptor Antagonists | AMGEN INC. (US) | 2009-09-10 | — | — | US | claimed |
| CN-101475571-A | Beta-carbolines cell cycle protein related kinase 2 inhibitor and use thereof | UNIV CHINA PHARMA (CN) | 2009-07-08 | — | — | CN | claimed |
| EP-1963285-A1 | BRADYKININ 1 RECEPTOR ANTAGONISTS | Amgen Inc. (US) | 2008-09-03 | — | — | EP | claimed |
| WO-2007067629-A1 | BRADYKININ 1 RECEPTOR ANTAGONISTS | AMGEN INC. (US) | 2007-06-14 | — | — | WO | claimed |
| CN-116867758-A | IRAK degradation agents and uses thereof | 凯麦拉医疗公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-115052627-A | IRAK degrading agents and uses thereof | 凯麦拉医疗公司 | 2022-09-13 | — | — | CN | disclosed |
| CN-114502158-A | IRAK degradation agent and application thereof | 凯麦拉医疗公司 | 2022-05-13 | — | — | CN | disclosed |
| US-10759749-B2 | Therapeutic agent for diabetes | JCR PHARMACEUTICALS CO., LTD. (JP) | 2020-09-01 | — | — | US | disclosed |
| EP-3508474-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | JCR Pharmaceuticals Co., Ltd. (JP) | 2019-07-10 | — | — | EP | disclosed |
| US-20190202781-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | JCR PHARMACEUTICALS CO., LTD. (JP) | 2019-07-04 | — | — | US | disclosed |
| CN-105339355-A | Novel CYP17 inhibitor/antiandrogen | ORION CORP | 2016-02-17 | — | — | CN | disclosed |
| CN-102762101-B | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | HIGH POINT PHARMACEUTICALS LLC | 2014-09-17 | — | — | CN | disclosed |
| US-5814654-A | TREATMENT OF HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS, ORGAN DISORDERS ASSOCIATED WITH ISCHEMIA, CEREBRO-ISCHEMIC DISORDERS, CELL PROLIFERATION, ENDOTHELIAL CELL INJURY | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1998-09-29 | — | — | US | disclosed |
| EP-0518352-B1 | Process for forming super high-contrast negative images and silver halide photographic material and developer being used therefor | DAINIPPON INK & CHEMICALS (JP) | 1998-04-22 | — | — | EP | disclosed |
| EP-0803501-A1 | Substituted guanidine derivatives and their use as Na+/H+ exchange inhibitors | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1997-10-29 | — | — | EP | disclosed |
| CN-1161334-A | Novel substd. guanidine derivs., process for prodn. thereof, and pharmaceutical uses thereof | SUMITOMO PHARMA (JP) | 1997-10-08 | — | — | CN | disclosed |
| EP-0787728-A1 | Substituted guanidine derivatives, process for production thereof, and pharmaceutical uses thereof | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1997-08-06 | — | — | EP | disclosed |
| US-5460919-A | Process of forming super high-contrast negative images and silver halide photographic material and developer being used therefor | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1995-10-24 | — | — | US | disclosed |
| US-5372911-A | Support having one or more hydrophilic colloidal layers, at least one layer contains pyridinium salt or derivative, quinolinium salt or derivative, or isoquinolinium salt or derivative | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1994-12-13 | — | — | US | disclosed |
| EP-0518352-A1 | Process for forming super high-contrast negative images and silver halide photographic material and developer being used therefor | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1992-12-16 | — | — | EP | disclosed |